Episode 725: Advancing Humane Cancer Therapy: GT Biopharma's ($GTBP) Next-Gen Immunotherapy & Clinical Progress
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
Episode 725: Advancing Humane Cancer Therapy: GT Biopharma's ($GTBP) Next-Gen Immunotherapy & Clinical Progress
-
Narrado por:
-
De:
A breakthrough that could reshape cancer treatment.
GT Biopharma (NASDAQ: GTBP) is advancing its next generation TriKE® platform, an innovative immunotherapy that activates the body’s own natural killer cells to identify and destroy cancer.
In this interview, Executive Chairman & CEO Michael Breen discusses the company’s latest clinical progress and the potential of its lead drug candidate, GTB-3650.
He also shares insights into the science behind TriKE®, the company’s pipeline for solid tumors and autoimmune diseases, and its mission to develop more humane cancer therapies that bring real hope to patients worldwide.
Learn more about GT Biopharma: https://www.gtbiopharma.com/
Watch the full YouTube interview here: https://youtu.be/jduKYNKHMIY
And follow us to stay updated: https://www.youtube.com/@GlobalOneMedia